<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151240</url>
  </required_header>
  <id_info>
    <org_study_id>cttq-focus-101</org_study_id>
    <nct_id>NCT02151240</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster</brief_title>
  <acronym>Focus-101</acronym>
  <official_title>A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cttq</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cttq</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Foscarnet Sodium and
      Sodium Chloride Injection in patients with herpes zoster, and observe incidence of
      Postherpetic neuralgia
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective rate</measure>
    <time_frame>8th days</time_frame>
    <description>Effective rate = (No. of patients achieving recovery+ markedly improvement)/Total patients No.×100%.
Recovery: curative index≥90%; Markedly improved: curative index 60%-89%; Improved: curative index 20%-59%; Ineffective: curative index＜20%. Where Curative Index= (patient's pre-treatment condition score - post-treatment condition score)/pre-treatment condition score ×100%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Postherpetic neuralgia</measure>
    <time_frame>3rd month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse event and serious adverse event</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV; Second administration: Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First administration: Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Second administration: Acyclovir for Injection 0.25g+ 0.9% Sodium Chloride Injection 250ml, IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foscarnet Sodium</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Patients with clinical diagnosis of Herpes Zoster, and able to be enrolled into the study
        ≤ 72 hours from appearance of rash; 2.18-65 years old, men and women; 3.VAS score≥4;
        4.Patients haven't receive any antiviral medication before enrollment; 5.Patients able to
        understand the study procedures, agree to participate and give written consent.

        Exclusion Criteria:

          1. Patients with history of allergy to Foscarnet Sodium or Acyclovir;

          2. Other combined infection (bacteria, fungi)

          3. Severe decline in immune function, or long-term use of corticosteroid and
             immunosuppressor

          4. Serious liver or renal function abnormalities (Aspartate Transaminase(AST) or alanine
             transaminase(ALT) ≥ 2.5x upper limits of normal(ULN), Creatinine(Cr) or Blood urea
             nitrogen(BUN)≥ 1x ULN)

          5. Women who are pregnant or lactating, and women of childbearing potential failed to use
             an adequate method of contraception to avoid pregnancy;

          6. Patients using other antiviral drugs;

          7. Long-term use of non-steroid anti-inflammatory drug, tricyclic antidepressant,
             anti-epileptic drugs or analgesic

          8. Current malignant tumor;

          9. Patients investigators consider as inappropriate to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianzhong Zhang, Doctor</last_name>
    <phone>86-18610275899</phone>
    <email>13911815813@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianzhong Zhang, Doctor</last_name>
      <phone>86-18610275899</phone>
      <email>13911815813@126.com</email>
    </contact>
    <investigator>
      <last_name>Jianzhong Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Breton G, Fillet AM, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis. 1998 Dec;27(6):1525-7.</citation>
    <PMID>9868672</PMID>
  </results_reference>
  <results_reference>
    <citation>Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J, Biron KK. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991 Jul 1;115(1):19-21.</citation>
    <PMID>1646585</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>herpes zoster, Foscarnet Sodium, Acyclovir, Postherpetic neuralgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
    <mesh_term>Foscarnet</mesh_term>
    <mesh_term>Phosphonoacetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

